Compile Data Set for Download or QSAR
Report error Found 115 Enz. Inhib. hit(s) with all data for entry = 11879
TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656477(US11919887, Compound 3b | rel-(2S,3R,4R,5S)-4-[[3-...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656481(US11919887, Compound 26 | (2R,3S,4S,5R)-4-[[3-(3,4...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656483(US11919887, Compound 9 | (2R,3S,4S,5R)-4-[[3-(2-et...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656485(US11919887, Compound 11 | US11919887, Compound 115...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656489(US11919887, Compound 15 | rel-(2S,3R,4R,5S)-N-(3-)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656491(US11919887, Compound 17 | US11919887, Compound 53 ...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656492(US11919887, Compound 18 | (2R,3S,4S,5R)-4-[[3-[2-(...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656493((2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656499(US11919887, Compound 25 | rel-(2R,3S,4S,5R)-4-[[3-...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656481(US11919887, Compound 26 | (2R,3S,4S,5R)-4-[[3-(3,4...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656506(US11919887, Compound 32 | rel-(2R,3S,4S,5R)-N-(3-c...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656516(US11919887, Compound 44 | rel-(2R,3S,4S,5R)-4-[[3-...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656521(US11919887, Compound 52 | rel-(2R,3S,4S,5R)-N-(3-c...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656491(US11919887, Compound 17 | US11919887, Compound 53 ...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656524(US11919887, Compound 55 | (2R,3S,4S,5R)-4-[[3-(2-e...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656493((2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656557(US11919887, Compound 89 | rel-(2S,3R,4R,5S)-4-[[3-...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656561(US11919887, Compound 116 | rel-(2S,3R,4R,5S)-4-[[3...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656562(US11919887, Compound 94)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656485(US11919887, Compound 11 | US11919887, Compound 115...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656561(US11919887, Compound 116 | rel-(2S,3R,4R,5S)-4-[[3...)
Affinity DataIC50: 10nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656474(US11919887, Compound 1)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656479(US11919887, Compound 5 | rel-(2R,3S,5R)-4-[[3-(3,4...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656487(US11919887, Compound 13 | rel-(2S,3R,4R,5R)-4-[[3-...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656496(US11919887, Compound 22 | rel-(2R,3S,5R)-4-[[3-(3-...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656494(rel-(2S,3R,5S)-4-[[3-(3-chloro-4-fluoro-2-methoxy-...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656501(US11919887, Compound 27 | (2R,3S,4S,5R)-4-[[3-(3,4...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656502(US11919887, Compound 28 | rac-(2S,3R,4R,5R)-4-[[3-...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656515(US11919887, Compound 41 | rel-(2S,3R,4R,5R)-4-[[3-...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656517(US11919887, Compound 45 | rel-(2S,3R,4R,5S)-4-[[3-...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656519(US11919887, Compound 47 | rel-(2R,3S,5R)-N-(3-carb...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656529(US11919887, Compound 60 | rel-(2R,3S,5R)-4-[[3-(3-...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656532(US11919887, Compound 64 | rel-(2S,3R,5S)-4-[[3-(3,...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656536(US11919887, Compound 68 | rel-(2S,3R,5S)-4-[[3-(4-...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656540(US11919887, Compound 72 | rel-(2R,3S,5R)-4-[[3-(4-...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656542(US11919887, Compound 74 | rel-(2R,3S,5R)-4-[[3-[2-)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656546(US11919887, Compound 78 | rel-(2S,3R,5S)-4-[[3-(3-...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656573(US11919887, Compound 105 | rel-(2R,3S,4S)-4-[[3-(3...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656581(US11919887, Compound 113 | 4-[[(2R,3S,4S,5S)-3-(3,...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656585(US11919887, Compound 138 | rel-(2R,3S,4S,5R)-4-[[3...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656586(US11919887, Compound 146 | 4-[[(2R,3S,4S,5R)-3-[2-...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656588(US11919887, Compound 151 | rel-(2S,3R,4R,5S)-4-[[3...)
Affinity DataIC50: 55nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656475(US11919887, Compound 2 | rel-(2S,3R,4R,5S)-4-[[3-[...)
Affinity DataIC50: 550nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656504(US11919887, Compound 30 | rel-(2R,3S,4S,5R)-4-[[3-...)
Affinity DataIC50: 550nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656507(US11919887, Compound 33 | rac-(2S,3R,4R,5R)-4-[[3-...)
Affinity DataIC50: 550nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656509(US11919887, Compound 35 | rac-(2R,3S,4R,5R)-4-[[3-...)
Affinity DataIC50: 550nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656511(US11919887, Compound 37 | rel-(2S,3R,4S,5R)-4-[[3-...)
Affinity DataIC50: 550nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656513(US11919887, Compound 39 | rel-(2R,3S,4R,5R)-4-[[3-...)
Affinity DataIC50: 550nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656523(US11919887, Compound 54 | rel-(2R,3S,5R)-4-[[3-(3,...)
Affinity DataIC50: 550nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM656530(US11919887, Compound 61 | rel-(2S,3R,5R)-4-[[3-(3-...)
Affinity DataIC50: 550nMAssay Description:Assay Protocol (7 Key Steps):1) To reach the final concentration in each well, 400 nL of each compound was pre-spotted (in neat DMSO) into polypropyl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/17/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 115 total ) | Next | Last >>
Jump to: